|
gptkbp:instance_of
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:activities
|
inhibits MD M2-p53 interaction
|
|
gptkbp:affects
|
cell cycle regulation
|
|
gptkbp:analyzes
|
drug resistance
|
|
gptkbp:appointed_by
|
oral route
|
|
gptkbp:author
|
Vassal G.
|
|
gptkbp:class
|
piperidine derivative
|
|
gptkbp:clinical_trial
|
high
moderate
ongoing
completed
oncology
Phase I
demonstrated efficacy
showed tumor reduction
|
|
gptkbp:collaborations
|
international
various universities
|
|
gptkbp:community
|
interested
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
antitumor activity
|
|
gptkbp:developed_by
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:discovered_by
|
gptkb:2004
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:enhances
|
p53 activity
|
|
gptkbp:established
|
MD M2 protein
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:future_plans
|
combination therapies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nutlin-3
|
|
gptkbp:impact
|
gptkb:significant
|
|
gptkbp:indication
|
gptkb:healthcare_organization
gptkb:neuroblastoma
|
|
gptkbp:ingredients
|
C16 H18 N2 O3 S
|
|
gptkbp:interacts_with
|
p53 protein
|
|
gptkbp:invention
|
gptkb:Daiichi_Sankyo
patented
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_studied_in
|
solid tumors
|
|
gptkbp:is_used_for
|
leukemia treatment
|
|
gptkbp:market
|
not commercially available
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:products
|
gptkb:battle
|
|
gptkbp:publishes
|
published in journals
|
|
gptkbp:receives_funding_from
|
grants
|
|
gptkbp:regulatory_compliance
|
under review
|
|
gptkbp:related_to
|
p53 pathway
|
|
gptkbp:research_areas
|
gptkb:Max_Planck_Institute
pharmacology
|
|
gptkbp:research_focus
|
tumor suppression
|
|
gptkbp:safety_features
|
under investigation
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
|
|
gptkbp:social_structure
|
contains sulfur
|
|
gptkbp:target_audience
|
cancer patients
|
|
gptkbp:targets
|
MD M2
|
|
gptkbp:treatment
|
favorable
under evaluation
with chemotherapy
with radiotherapy
|
|
gptkbp:type_of
|
675576-98-4
|
|
gptkbp:used_in
|
cancer therapy
|